Boston Scientific stock fell 1.46 percent as cyber risk hit guidance
π Boston Scientific stock dropped 1.46% to $42.60 after a cybersecurity incident threatened its Q3 and full-year guidance.
π» Unauthorized activity began on August 25, 2026, disrupting manufacturing and shipments before distribution was substantially restored.
π Q2 2026 revenue grew 7.5% year-over-year to $5.442 billion with GAAP net income rising to $907 million.
π» Analyst Oppenheimer lowered its price target from $85 to $65 due to concerns over the cyber incident's impact on guidance.
β οΈ The company faces weaker momentum in its WATCHMAN product line and competitive pressure in electrophysiology.
π Boston Scientific is scheduled to discuss third-quarter results and an updated outlook on October 28, 2026.
Bullish Signals
- Q2 2026 revenue increased 7.5% year-over-year to $5.442 billion, demonstrating underlying business strength despite the cyber incident.
- GAAP net income attributable to common shareholders rose to $907 million from $797 million in the prior year period.
Risk Factors
- A cybersecurity incident beginning August 25, 2026, disrupted manufacturing and order processing, raising risks to Q3 and full-year guidance.
- Analyst Oppenheimer cut its price target from $85 to $65 due to concerns that the company may not meet previous net sales growth and adjusted EPS guidance.
Full Analysis
Boston Scientific stock fell 1.46% to $42.60 on October 2, 2026, following a cybersecurity incident that raised concerns about the company's ability to meet its previously issued guidance for the third quarter and full year. The company disclosed unauthorized activity starting August 25, 2026, which disrupted manufacturing, order processing, and customer shipments, though distribution was substantially restored by the time of the report.
Despite the cyber risk, Boston Scientific reported strong second-quarter 2026 financial results with revenue rising 7.5% to $5.442 billion and GAAP net income increasing to $907 million. However, the incident led to a significant downgrade from analyst Oppenheimer, which cut its price target from $85 to $65, while other analysts maintain a moderate buy consensus with an average target of $70.19.
The company faces ongoing operational challenges including weaker momentum in its WATCHMAN product line and competitive pressure in the electrophysiology sector. Investors are now focused on the upcoming earnings call scheduled for October 28, 2026, where Boston Scientific plans to provide an updated operational and financial outlook regarding the impact of the cyber incident.